Cargando…

Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis

OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lingning, Fan, Yan, He, Jiangmen, Liu, Heng, Chen, Feng, Dan, Hongying, Zhao, Juan, Zhang, Jiao, Wang, Tao, Liu, Xinru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283059/
https://www.ncbi.nlm.nih.gov/pubmed/35845579
http://dx.doi.org/10.1155/2022/5260235
_version_ 1784747251926564864
author Wang, Lingning
Fan, Yan
He, Jiangmen
Liu, Heng
Chen, Feng
Dan, Hongying
Zhao, Juan
Zhang, Jiao
Wang, Tao
Liu, Xinru
author_facet Wang, Lingning
Fan, Yan
He, Jiangmen
Liu, Heng
Chen, Feng
Dan, Hongying
Zhao, Juan
Zhang, Jiao
Wang, Tao
Liu, Xinru
author_sort Wang, Lingning
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI, CMB, Wan-Fang, and VIP. Outcomes included HAMD reduction from baseline, response rate, and adverse events rate. Review Manager 5.3 was used in the present meta-analysis. RESULTS: 16 studies including 1409 participants were included in the present study. In comparison of single Shuganjieyu capsule versus regular antidepressant, 8, 6, and 4-week HAMD reduction of the Shuganjieyu group were significantly higher (8-week MD: 3.1 (1.54, 4.66), p < 0.0001; 6-week MD: 0.71 (0.10, 1.31), p=0.02; and 4-week MD: 0.82 (0.34, 1.30), p=0.0008), response rates were comparable for the two groups (OR: 1.51 (0.87, 2.63), p=0.014), and the adverse event rate of the Shuganjieyu group was significantly lower (OR: 0.22 (0.15, 0.32), p < 0.00001). In comparison of combination of Shuganjieyu capsule with regular antidepressant versus regular antidepressant alone, the 8, 6, 4, 2, and 1-week HAMD reduction and response rate of combination of Shuganjieyu with the regular antidepressant group were significantly larger (8-week MD: 3.2 (1.34, 5.06), p=0.0007; 6-week MD: 4.00 (2.72, 5.28), p < 0.00001; 4-week MD: 3.33 (1.94,4.73), p < 0.00001; 2-week MD: 2.69 (1.34, 4.03), p < 0.0001; 1-week MD: 2.27 (0.69, 3.86), p=0.005; and response rate OR: 4.69 (2.27, 9.68), p < 0.0001) and the adverse event rate was comparable for the two groups (OR: 1.26 (0.73, 2.17), p=0.41). CONCLUSION: Compared with regular antidepressants, single Shuganjieyu capsule has similar efficacy and better safety profile; when Shuganjieyu capsule is combined with regular antidepressants, the efficacy is improved significantly without increasing adverse events. Therefore, Shuganjieyu capsule was effective and safe for postpartum, making it worth further investigation and popularization.
format Online
Article
Text
id pubmed-9283059
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92830592022-07-15 Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis Wang, Lingning Fan, Yan He, Jiangmen Liu, Heng Chen, Feng Dan, Hongying Zhao, Juan Zhang, Jiao Wang, Tao Liu, Xinru Evid Based Complement Alternat Med Review Article OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI, CMB, Wan-Fang, and VIP. Outcomes included HAMD reduction from baseline, response rate, and adverse events rate. Review Manager 5.3 was used in the present meta-analysis. RESULTS: 16 studies including 1409 participants were included in the present study. In comparison of single Shuganjieyu capsule versus regular antidepressant, 8, 6, and 4-week HAMD reduction of the Shuganjieyu group were significantly higher (8-week MD: 3.1 (1.54, 4.66), p < 0.0001; 6-week MD: 0.71 (0.10, 1.31), p=0.02; and 4-week MD: 0.82 (0.34, 1.30), p=0.0008), response rates were comparable for the two groups (OR: 1.51 (0.87, 2.63), p=0.014), and the adverse event rate of the Shuganjieyu group was significantly lower (OR: 0.22 (0.15, 0.32), p < 0.00001). In comparison of combination of Shuganjieyu capsule with regular antidepressant versus regular antidepressant alone, the 8, 6, 4, 2, and 1-week HAMD reduction and response rate of combination of Shuganjieyu with the regular antidepressant group were significantly larger (8-week MD: 3.2 (1.34, 5.06), p=0.0007; 6-week MD: 4.00 (2.72, 5.28), p < 0.00001; 4-week MD: 3.33 (1.94,4.73), p < 0.00001; 2-week MD: 2.69 (1.34, 4.03), p < 0.0001; 1-week MD: 2.27 (0.69, 3.86), p=0.005; and response rate OR: 4.69 (2.27, 9.68), p < 0.0001) and the adverse event rate was comparable for the two groups (OR: 1.26 (0.73, 2.17), p=0.41). CONCLUSION: Compared with regular antidepressants, single Shuganjieyu capsule has similar efficacy and better safety profile; when Shuganjieyu capsule is combined with regular antidepressants, the efficacy is improved significantly without increasing adverse events. Therefore, Shuganjieyu capsule was effective and safe for postpartum, making it worth further investigation and popularization. Hindawi 2022-07-07 /pmc/articles/PMC9283059/ /pubmed/35845579 http://dx.doi.org/10.1155/2022/5260235 Text en Copyright © 2022 Lingning Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Wang, Lingning
Fan, Yan
He, Jiangmen
Liu, Heng
Chen, Feng
Dan, Hongying
Zhao, Juan
Zhang, Jiao
Wang, Tao
Liu, Xinru
Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title_full Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title_fullStr Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title_full_unstemmed Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title_short Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
title_sort efficacy and safety of shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression: a meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283059/
https://www.ncbi.nlm.nih.gov/pubmed/35845579
http://dx.doi.org/10.1155/2022/5260235
work_keys_str_mv AT wanglingning efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT fanyan efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT hejiangmen efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT liuheng efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT chenfeng efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT danhongying efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT zhaojuan efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT zhangjiao efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT wangtao efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis
AT liuxinru efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis